Imaging Therapeutics, Inc. Receives FDA Approval for Hip Bone Mineral Density

REDWOOD CITY, Calif., Oct 22, 2008 (BUSINESS WIRE) -- Imaging Therapeutics, Inc has received marketing clearance from the United States Food and Drug Administration to market its OsDx(TM) Hip Bone Mineral Density (BMD) system. OsDx Hip BMD is a stand-alone x-ray image-processing software system intended to provide an estimate of BMD of the proximal femur using standard antero-posterior hip or pelvis radiographic images.

This information may be used by physicians in the assessment of osteoporosis.
According to the 2004 Surgeon General Report on Bone Health and Osteoporosis, an estimated 10 million Americans suffer osteoporosis while another 34 million Americans are at risk of disease.

source: Marketwatch